FDA green lights Insilico’s AI-designed NLRP3 inhibitor ISM8969 for Phase I clinical trial in Parkinson’s disease

Insilico Medicine has received investigational new drug clearance from the US Food and Drug Administration for ISM8969, an oral, brain-penetrant inhibitor of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, as the company prepares first-in-human safety testing and expands its partnership with Hygtia Therapeutics

Insilico Medicine has reported that it has received investigational new drug (IND) clearance from the US Food and Drug Administration for ISM8969, an orally administered inhibitor of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome that the company intends to develop for Parkinson’s disease and other disorders linked to neuroinflammation.

The clearance allows Insilico to begin a Phase I clinical trial in healthy volunteers, with the programme designed to assess safety, tolerability and pharmacokinetics and to determine dose levels to support subsequent studies.

The IND decision places ISM8969 among a growing pipeline of candidates that attempt to tackle Parkinson’s disease through immune and inflammation pathways rather than dopamine replacement alone. Parkinson’s disease remains a progressive neurodegenerative condition that leads to the loss of dopaminergic neurons – most visibly through tremor, rigidity and bradykinesia – while also producing non-motor features that can include sleep disturbance, depression and cognitive impairment.

Available treatments can relieve symptoms, yet they do not reliably alter the underlying course of disease which has promoted research in targets that may contribute to neurodegeneration.

NLRP3 has drawn attention because it acts as a central molecular switch within the innate immune system. In many contexts, the NLRP3 inflammasome helps to coordinate a defensive response to cellular stress or infection. However, excessive or persistent activation can drive the release of inflammatory mediators, including cytokines and chemokines and can amplify tissue injury. In the brain, this form of chronic neuroinflammation has been proposed to accelerate neuronal dysfunction and loss which has made NLRP3 inhibition an attractive but still clinically unproven strategy in neurodegenerative disease.

“NLRP3 has emerged as a key contributor to chronic neuroinflammation and disease progression in neurodegenerative disorders,” Dr. Carol Satler said, senior vice-president for clinical development (non-oncology) at Insilico Medicine.

“A novel NLRP3 inhibitor, ISM8969 with the desired brain penetrant property made possible via our AI-powered design process, offers the potential to advance Parkinson’s disease treatment to the next generation,” she added.

A central development risk for many anti-inflammatory approaches in neurology involves drug exposure in the central nervous system, because the blood–brain barrier restricts entry for numerous small molecules and biologics. Insilico has positioned ISM8969 as a brain-penetrant compound which means it should reach pharmacologically relevant concentrations within the brain rather than act only in peripheral tissues.

The company has argued that this attribute could support a stronger rationale for Parkinson’s disease than for NLRP3 inhibitors that do not cross the blood–brain barrier, although clinical data will determine whether this theoretical advantage translates into measurable patient benefit.

Insilico said that it discovered and optimised ISM8969 with Chemistry42, the generative chemistry platform within its broader Pharma.AI suite. The company has described Chemistry42 as an engine that supports the design and prioritisation of candidate structures across stages that include hit identification and lead optimisation.

In December 2024, Insilico nominated ISM8969 as an orally administered preclinical candidate for NLRP3 and it has since progressed the compound to regulatory clearance for human testing.

While Phase I studies do not test efficacy against Parkinson’s disease itself, they represent a key inflection point for any central nervous system programme. First-in-human trials typically examine dose escalation across small cohorts, with intensive safety monitoring and repeated blood sampling to define exposure profiles, including peak concentration, overall exposure over time and elimination rates.

These studies can also provide early evidence about whether a candidate achieves concentrations compatible with the intended mechanism. For neuroinflammation targets, developers may also attempt exploratory biomarker analysis, although such signals can remain difficult to interpret in healthy volunteers.

Alongside the IND clearance, Insilico has announced a co-development collaboration agreement with Hygtia Therapeutics intended to accelerate global development of ISM8969. Under the arrangement, the two companies have agreed to share global rights and interests in the programme on a 50–50 basis, while Insilico remains eligible to receive up to US$66 million in upfront and milestone payments. Insilico will lead initial clinical development and Phase I execution, while Hygtia will take responsibility for later-stage global studies, regulatory submissions and commercialisation activity.

The agreement also reflects a wider pattern in which specialist biotechnology companies seek to pair rapid early discovery and translation with partners that can fund and manage longer, more expensive late-stage development. For Parkinson’s disease, this challenge has proven acute where trials often need long durations to detect disease-modifying effects, endpoints can be complex, and recruitment can require careful phenotyping to reduce heterogeneity.

Insilico has framed ISM8969 as part of a broader demonstration that generative artificial intelligence can shorten timelines in small-molecule discovery. The company said that traditional early-stage discovery can take several years, while its internal model has supported the nomination of multiple preclinical candidates on shorter schedules, with relatively limited synthesis and testing per programme. Such claims have helped to fuel investor enthusiasm for AI-enabled discovery, although the industry continues to debate how often speed at the design stage translates into higher clinical success rates.

The company has also highlighted a growing collaboration portfolio with large pharmaceutical organisations, including Sanofi, Eli Lilly, Exelixis and Menarini, as it attempts to validate its approach across multiple disease areas. Its pipeline focus spans conditions that include fibrosis, oncology, immunology, pain and metabolic disease, with Pharma.AI positioned as a platform that can support both internal programmes and external partnerships.

Insilico listed on the Main Board of the Hong Kong Stock Exchange on 30 December 2025 under stock code 03696.HK, which has increased scrutiny of its ability to convert platform claims into clinical milestones.

For clinicians and researchers, the significance of ISM8969 will depend on whether NLRP3 inhibition can shift meaningful outcomes in Parkinson’s disease without unacceptable immune-related adverse effects. Inflammasome biology intersects with host defence, so sustained inhibition carries theoretical risks that can include altered infection susceptibility, even if the degree of risk varies across compounds and dosing strategies. The Phase I programme will therefore need to clarify not only tolerability but also exposure margins that support chronic administration, which Parkinson’s disease would likely require.

Insilico has presented the start of human studies as a step towards a novel treatment paradigm for neurodegenerative disease, yet the history of Parkinson’s research suggests that biological plausibility rarely guarantees clinical success. The IND clearance has, nonetheless, moved ISM8969 from computational design and preclinical evaluation into a regulatory framework that demands reproducible manufacturing, rigorous safety monitoring and clinically relevant decision-making.